1

Molecular Partners:

BuildingTomorrow’s Breakthroughs

Corporate Presentation

Molecular Partners AG, Switzerland (SIX: MOLN)

March 15, 2019

2

Molecular Partners: A Swiss Biotech developing innovative protein drugs

DARPin® platform as source of mono/multi-specific protein drugs

Rapid cycle of innovation to test novel therapeutic design

Validation in >1.8k patients treated to date (mainly Abicipar)

DARPin®

ENGINE

Abicipar: Phase 3 in wet AMD

MP0250: Phase 2 in MM and NSCLC

MP0274: Phase 1 in Her2 positive cancer indications

MP0310: First-in-human in multiple cancer indications in 2019

DARPin®

PIPELINE

TEAM

WORK

130 co-workers – purpose driven, evolutionary organization

Partnership with Allergan on Abicipar, ophthalmology assets

New partnership with Amgen on MP0310

CAPITALMultiple near-term catalysts with significant value creation potential

Well financed: on-track to steady income with Abicipar launch (2020e)$

3

Dr. Patrick Amstutz, CEO

Co-founder, former CBO & COO

Member of the Board of Directors

PhD in molecular biology from UZH

Dr. Andreas Harstrick, CMO, MD

30 years of experience in oncology

Developed multiple mAb oncology products

Senior positions at Merck-Serono, Imclone, Eli Lilly

Dr. Michael Stumpp, COO

Co-founder

PhD and postdoc from UZH;

research in Tokyo, London

Andreas Emmenegger, CFO

Former CFO Glycart, Finance Roles at Roche

>20 years experience as CFO of private & listed

companies and in fund raising, IPOs

Dr. Pamela Trail, CSO

>30 years of experience in cancer drug discovery

Senior positions at Regeneron, Medimmune, SGEN,

Bayer, BMS

Experienced Management Team & Board of Directors

Bill Burns, Chairman Former CEO of Roche Pharmaceuticals

Former board member of Roche, Genentech,

Chugai Pharmaceuticals, Shire

Göran Ando, Vice Chairman Former Chairman, Novo Nordisk

Former CSO, Pharmacia

Gwen Fyfe Former VP, Oncology Development at

Genentech

Steven H. Holtzman President and CEO, Decibel Therapeutics

Former EVP, Biogen

William “Bill” Lee EVP Research, Gilead

Petri Vainio Managing Director, Essex Woodlands

Ventures

EX

EC

UT

IVE

MA

NA

GE

ME

NT

BO

AR

D O

F D

IRE

CT

OR

S

4

DARPin® Proteins: Nature’s Choice for Multi-Specific Binding

• Large size: 150 kDa

• Complex architecture: 4 proteins with 12 domains

• Target binding via flexible surface loops (CDRs)

MONOCLONAL ANTIBODIES DARPin® Protein(s)

Binding region /

specificity

15 kDa

150 kDa

SCALE

DARPin® moduleBinding regions /

specificity

Multi-DARPin® product candidate

• High affinity and specificity

• Low immunogenicity potential

• Tunable half life• Small size: 15 kDa (1/10 of monoclonal antibody)

• Simple architecture: 1 protein with 1 domain

• Target binding via rigid surface structure

5

DARPin® Engine: Selecting Novel Therapeutic Designs toMatch Desired Function

DARPin® module selection Opening novel Therapeutic

Design Space

Therapeutic Design matches

its function

Selecting the «optimal»

Therapeutic Design

Multi-DARPin® product candidates

DARPin® Library with

1012 modules

Target(s)

Identified DARPin® modules

with high target affinity

6

A Balanced and Robust Portfolio

AMD: age-related macular degeneration; DME: diabetic macular edema; NSCLC: non-small cell lung cancer

Preclinical Phase 1 Phase 2 Phase 3Commercial

RightsO

nco

log

yI/

OO

ph

tha

lmo

log

yProduct

CandidatesIndication/

Focus

MP0250 Multiple Myeloma, PI combo

MP0250 EGFR-mutated NSCLC

MP0274 HER2 positive

MP0310 FAP x 4-1BB

Abicipar Neovascular AMD

Abicipar DME

Additional proprietary

DARPin® candidates

Various

in I/O

Additional

DARPin® candidates

Various in

Ophthalmology

MP0250 Multiple Myeloma, IMiD study

DA

RP

in®

Engin

e:

So

urc

e o

f P

rod

uct C

an

did

ate

s

7

Tree of Evolution of DARPin® Approaches

Abicipar: Local activity,

high affinity bindingSystemic

validation

Bi-Specifics

MP0250

Incre

asin

g le

ve

l of

Inn

ova

tion &

Diffe

ren

tiatio

n

Direct Tumor

Cell Killers

MP0274

Next level of immune

cell targeting

MHC-peptides

Local

Agonists

MP0310

FAP x CD40

DARPin® Platform

Mono-Specifics

8

Oncology Deep Dive: MP0250, MP0274, MP0310, Research

9

MP0250: Our First Multi-DARPin® Product Candidate

SOC, standard of care; HSA, human serum albumin.

VEGF

DARPin®HGF

DARPin®

HSA

DARPin®

Medical Need: Some tumors develop adaptive

resistance to SOC by up-regulating VEGF and HGF

MoA: MP0250 inhibits both VEGF and HGF

simultaneously

Blocking these adaptive escape pathways may

restore clinical sensitivity to SOC

Status: Phase 2 in MM and NSCLC ongoing

Phase 1: safe up to 8 mg/kg/3weeks

HSA

DARPin®

HGF

(c-MET)

VEGF

Upregulation of escape

pathways after SOCMedical need: Agents that block

escape pathways to SOC

HGF

(c-MET)

VEGF

MP0250

10

50,000 – 100,000

>100,000

MP0250: Potential to Treat Several Indications MM and EGFR-mut NSCLC selected initially

1) Including US/5EU/JP. Datamonitor.

Head and neck

squamous cell

EGFR-mutated

NSCLC

Multiple myeloma

Hepatocellular

carcinoma

Colorectal cancer

Nasopharyngeal

Gastric cancer

Renal cancer

Anal cancer

<50,000

INCIDENCE:1

MP0250

11

Unmet Medical Need in Multiple Myeloma (MM)

Relapsed

c-MET

89%

Newly diagnosed

Activa

ted

-c-

ME

T r

ece

pto

r

28%

c-MET

On partial remission

2%

c-MET

Dynamic activation of the HGF pathway during disease progression1. HGF is highly overexpressed in bone marrow

biopsies of multiple myeloma patients

Bone marrow

tumor Score 3+6/8

patient samples

1. Moschetta M, et al. Clin Cancer Res 2013;19:4371-82

Bone marrow

tumor Score 2+

Solid tumor

Score 1+

2/8 patient samples

0/8 patient samples

MP0250

MM remains incurable for most patients as cells acquire adaptive resistance to currently available therapies

Relapse inevitable

Time to relapse shortens with every treatment cycle

Quality of response tends to diminish

No current drug in MM is addressing

adaptive VEGF and HGF resistance

12

Testing how MP0250 can revert Adaptive Resistance in MM

1) Hajek, R. Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure.

In “Multiple Myeloma: A Quick Reflection on the Fast Progress” (2013).

Illustrative course of disease of a MM patient1

IMiD

PI IMiD

PI

MP0250

MP0250

+

PIor or

our «initial» trial

13

MP0250 Phase 2 Study in MM: Promising Signs of Efficacy

Data cut-off: 31 January 2019. dose level: 8mg/kg/3weeks.Partial

Response

Very Good

Partial Response

Stable

Disease

Progressive

Disease

On

Treatment

70 80

Treatment duration (weeks)

Minor

Response

MP0250

Patient population: Patients with MM with

≥ 2 prior lines of treatment, including IMiD and PI,

and no response or early relapse

Treatment regimen: Velcade®/Dexamethasone

plus MP0250

5 of 8 patients with objective responses (cohort 1)

3 of 4 patients coming directly from a PI-based

regimen responded in cohort 1 (*)

Durable remission observed in heavily pretreated

patients

MP0250 (8mg/kg) combined with Velcade® has

shown tolerable safety profile

Study ongoing with additional patients ( )10 20 30

Cohort

1E

xpansio

n

*

**

*

Pt. A

14

MP0250 Case Study: Patient A (4th line, coming from PI)

1st line:

Cyclo/Thal/Dex

SD

SD

VGPR

2nd line:

Bor/Dex

4th line:

MP0250/

Bor/Dex

time

Dis

ea

se

se

ve

rity

(co

nce

pti

on

al)

3rd line:

Bor/

Len/

Dex

1 year >1.5 years, ongoing

PD

PD

PD

Female 63y, MM IgG kappa diagnosed in May 2016

Prior MM Therapy:– 1st Line: Cyclo/Thal/Dex; Best Response: SD

– 2nd Line: Bor/Dex; Best Response: SD

– 3rd Line: Bor/Len/Dex; Best Response: PD

Current Treatment: 4th line - MP0250– Start: Aug 2017, ongoing

– Safety: Hypertension, Polyneuropathy

– Best Response: VGPR, ongoing

15

MP0250 Positioning in MM and Our «planned» Trials

1. Including US/5EU/JP. Datamonitor, August 2018.

Global market value of

MM treatment:

$13 billion

expected to exceed

$20 billion

by 2022

(CAGR: 13%)1

n 30,0001n >100,0001

1st Line

Therapy

2nd

Line

4th

Line

3rd

Line

IMiDor

mAb

PI+

Transplant

or

mAb

+

PI

IMiD75%

25%

Multiple myeloma: 2nd most common

blood cancer

MP0250

MP0250

+

PI

MP0250

+

IMiD

our «planned» trialsMP0250 has the potential to become

backbone for later lines of treatment

16

No targeted drug approved

for patients progressing on Tagrisso®

treatment – high unmet medical need

Phase 2 ongoing in the US

Patient population: Patients with

EGFR-mut NSCLC who have failed to

respond to Tagrisso ®

Treatment regimen: Tagrisso® plus

MP0250

Unmet Need in EGFR-mutated NSCLC

PFS-based data from the FLAURA and AURA3 study;

TKI, Tyrosine Kinase Inhibitor

3rd Line:

Chemotherapy

TREATMENT

OPTION 2

1st Line:

1st Generation TKI

2nd Line:

Tagrisso®

PFS: ~10.2 months PFS: ~8.5 months

PFS: ~18.9 months

TREATMENT

OPTION 1

EGFR-

mutation

T790 -

mutationother - mutations

cMET- amplification

HGF up-regulation/

cMET pathway activation

~10%

Tagrisso Chemotherapy

MP0250

MP0250

17

Unique Potential of MP0250 in EGFR-mut NSCLC

1. Including actively treated, Stage IIIb and Stage IV prevalent cases in US/5EU/JP. Datamonitor, August 2018;

Tang et al Oncotarget 2016: Activating EGFR mutations are found in ~40% (Asia), ~20% (US), and ~15% (EU)

Global market value

(EGFR NSCLC):

ca. $2.8 billion

expected to exceed

$3.5 billion

by 2023 (CAGR: 5%)1

n=35,0001 n 15,0001

1st Line

Therapy

2nd

Line

3rd

Line

Tagrisso®

Iressa® or

Tarceva® Tagrisso ®

MP0250

n=20,0001

Tagrisso®

MP0250

Tagrisso ®

Treatment

option 1

Treatment

option 2

4th

Line

+

+

MP0250

P2 Trial

MP0250

No targeted drug approved

after patients progress under

Tagrisso® treatment

18

MP0274: Killing HER2+ Cells by New MoA

HER2

DARPin® A

HER2

DARPin® B

HSA

DARPin®

Medical need: despite good antibody-based

HER2+ treatments, eventually patients progress

Novel mode of action: MP0274 is an allosteric

inhibitor blocking HER2- and HER3 signaling and

inducing apoptosis

No need for drug conjugation (ADC) for direct

tumor cell killing

Status: Phase 1 dose escalation in HER2 positive

tumor patients that have progressed on SOC

ongoing; Recruitment of first patient cohort

completed

MP0274

Bi-paratopic DARPin®

MP0274 locks Her2 into fully

inactive conformation

Her2

«Open»

Her2

«Locked»

Apoptosis: Tumor

cell suicide

MP0274

HSA

DARPin®

19

1 0 0 1 0 1 1 0 2 1 0 3 1 0 4 1 0 5 1 0 6

0

2 0

4 0

6 0

8 0

1 0 0

New MoA may help patients who do not adequately respond to current therapies

MP0274 is a Highly Potent Tumor Cell Killer

Tumor Cell ApoptosisBT474

Tumor Cell KillingBT474

[nM]

0 100 101 102 103

100

80

60

40

20

0

(Herceptin®/Perjeta®)

MP0274

% K

illin

g

[nM]

MP0274

Ado-trastuzumab emtansine

Trastuzumab/Pertuzumab

(Kadcyla®)

100

80

60

40

20

0

100 101 102 104103 105 106

MP0274

20

UNBLOCK

DIRECT

KILL

ENGAGE

Tumor Cells

Tumor Stroma

Cells

MODULATE

PRIME &

ACTIVATE

Immune CellT cells

ENGAGECytotoxic Immune Cells

UNBLOCKCheckpoint Approaches

T cells

DIRECT KILLDirect Tumor Cell Killing

Tumor cells

MODULATETumor Microenvironment Modulators

Tumor / Stromal cell interactions

PRIME & ACTIVATELocalized Immune Modulators

Antigen-presenting cells, T cells

DARPin® Strategy in Oncology

MP0274

MP0250

MP0310

pMHCs

21

DARPin® Strategy in Immuno-Oncology

Tumor Stroma

Cells

Immune

Cell

4-1BB, others

CD-3

FAP

Tumor antigen

PD-1

Tumor Cells

ENGAGE

Tumor Cell

Immune

Cell

ACTIVATE

PD-1 mAB

22

Our Vision to Expand the Therapeutic WindowThrough Tumor-Localized Immune Modulation

Current IO therapeutics that

activate the immune system

(agonists) throughout the

body show systemic side

effects that can limit the

effective dosing

Tumor-localized IO

therapeutics that activate

immune cells preferentially

within the tumor may both

increase efficacy and

reduce systemic toxicities

tumor

stroma

tumor cells

tumor cells

healthy cells

activated

T cell

activated

T cell

resting

T cell

MP0310

23

DARPin® Toolbox: Tumor-LocalizedImmune Modulators

Tumor-localized immune modulators – overcoming the limitation of systemic side effects

OX-40 4-1BB CD40 Other Targets

Solid Tumor

TAA*TAA x 4-1BB

Tumor

Stromal

Antigen

FAP x 4-1BB

MP0310FAP x CD40

Hematologic

TAATAA x OX40 TAA x 4-1BB TAA x CD40

Immune Modulator

Lo

cali

zer

*Tumor-Associated Antigen (TAA)

MP0310

24

MP0310 (FAP x 4-1BB): Activating T-cells in the Tumor

HSA, human serum albumin.

Medical need: most current 4-1BB agonists activate

T-cells and NK cells systemically and are limited by

side-effects

MoA: MP0310 uses binding to FAP – a tumor

stromal target – to cluster and activate T-cells

primarily in the tumor

Status: MP0310 is in preclinical development and

partnered with Amgen. Phase 1 to start in H2 2019

4-1BB

DARPin®

FAP

DARPin®

HSA

DARPin®Illustrative graphic

MP0310

DARPin® modules

Immune modulator Localizer Half-life extender

MP0310

+ +

+ MP0310

25

Intratumoral CD8 T cells

Combined Therapy with MP0310 and TAA x CD3 Bi-Specific Results in Significant Increase of Intratumoral CD8+ T Cells

Veh

icle

TAA x

CD3

TAA x

CD3

+ M

P03

10

0

10000

20000

30000

40000

Nu

mb

er

of

hC

D8

T c

ells

pe

r 0

.2 g

tu

mo

r

***

**

FAP-Mediated Tumor

Accumulation of MP0310

HT-29-T-implanted NSG mice

Tumor growth inhibition

PBMC humanized HT-29 xenograft model

0

500

1000

1500

2000

Treatment days

Me

an

tu

mo

r v

olu

me

(m

m3)

0 3 7 10 14 16

Vehicle

TAA x CD3

TAA x CD3+ MP0310

mFAP x 4-1BBno-FAP x 4-1BB

Tumor

MP0310

26

Peptide-MHCs – DARPin® approach for «un-accessible» targets

Extracellular

targets

MHC

peptide

Intracellular

targets

Most targets are in the intracellular space and not accessible with antibody-based approaches

Antibody-based approaches:

Limited success with mAbs, BiTEs, CAR-T cell, etc. to

target pMHC complexes

Soluble T cell receptor approaches:

limited by biophysical characteristics and

rather low affinity to pMHCs

DARPin®-based approaches:

Research projects to test DARPin® binders to pMHCs

in oncology and virology

Engage

27

Program Deep Dive: Abicipar

28

Abicipar has Potential to be First Fixed 12 Week anti-VEGF

Source: Allergan presentation, 06 Dec 2018, VA visual acuity, OCT optical coherence tomography

Medical Need: current anti-VEGFs in nAMD are mostly

dosed monthly or extended to bi-monthly, leading to high

patient burden and under-dosing in real-world settings

MoA: Abicipar is the only long-acting anti-VEGF and has

shown to be the first fixed 12-week nAMD drug, lowering

patient burden given full effectiveness in real world setting

Status: Allergan plans FDA filing in H1 2019 and launch in

2020 and plans to start DME Phase 3 in H2 2019

VA defect in nAMD

OCT in nAMD

Choroidal

Neovascularization

Abicipar

29

Phase 3 Efficacy Results (SEQUOIA study, 1yr data)

Source: Allergan July, 2018 and October 2018

Primary Endpoint: STABLE VISION Abicipar

Q8 and Q12 Non-Inferior to Ranibizumab Q4

Secondary Endpoint: Change in BCVA From Baseline Abicipar

Q8 and Q12 in SEQUOIA Non-Inferior to Ranibizumab

Secondary Endpoint: Change in CRT similar across in all

groups

Abicipar

30

Allergan is further optimizing the material for potential launch 2020

Primary and secondary endpoints support abicipar potential to become

the first fixed 12-week anti VEGF in nAMD

Overall safety events between abicipar and ranibizumab were comparable

– Intraocular inflammation potential was higher for Abicipar (15%) vs ranibizumab (< 1%)

–Majority of inflammation was mild to moderate and were treated with topical corticosteroids

Further optimized Abicipar material was produced and is currently being tested

in clinical trial (MAPLE) – Allergan expects results in H1 2019

Abicipar

31

Partnerships

32

Leveraging our DARPin® Engine via Partners

Strategy: Broaden and accelerate our activities & cross-finance our proprietary pipeline

Partnership to leverage the DARPin®candidates in ophthalmology (no cost share)

• Total of USD 360m in potential future milestones

• Tiered royalties: Low double-digit to mid-teens

Gilead-supports research project to test if

DARPin® molecules can specifically bind to

peptide-MHC complexes

Partnership to test MP0310 in combination

with other IO drug candidates (cost share for

some clinical trials)

• USD 50mio upfront payment, USD 497mio in

clinical, regulatory and commercial milestones

• Double-digit, tiered royalties up to the high teens

Collaboration to test MP0250 combination with

Tagrisso® in EGFR-mut NSCLC

• No MP0250 rights attached

33

Outlook & Conclusions

34

DARPin® Engine: Source for candidates with novel therapeutic designs

Advanced and balanced DARPin® Portfolio

–Abicipar in pivotal trial with potential to be first fixed 12-week anti VEGF in nAMD

–MP0250 in P2 pioneering a new MoA in MM, P2 in NSCLC & MP0274 in P1

–Research in oncology focus areas set-up to deliver highly innovative designs of

candidates (tumor local agonists, pMHC DARPins, …)

Organizational focus on product innovation and company growth

Partnerships to accelerate development of DARPin® candidates

Well financed & on-track towards steady income with expected Abicipar launch in

2020 by AGN

Investment Case

35

Accelerating Progress in 2019 and Beyond

2019 2020

Abicipar BLA filing planned (H1)

DME: P3 start

MAPLE: data of further optimized material (H1)

nAMD Launch

MP0250 Additional data: ongoing P2 MM trial

Start of P2 PI and IMiD-combo trial in MM

Interim results from P2 NSCLC trial

Interim P2 data: PI-combo trial

Interim P2 data: IMiD-combo trial

MP0274 First safety & interim efficacy data

MP0310 FIH with MP0310 (mono therapy) MP0310 combination trials

Research Advance DARPin® candidates

Establish novel therapeutic designs

CapitalFunding into H2 2020 (excl. any future proceeds related to Abicipar and partnerships)

36

Tree of Evolution of DARPin® Approaches

Abicipar: Local activity,

high affinity bindingSystemic

validation

Bi-Specifics

MP0250

Incre

asin

g le

ve

l of

Inn

ova

tion &

Diffe

ren

tiatio

n

Direct Tumor

Cell Killers

MP0274

Next level of immune

cell targeting

MHC-peptides

Local

Agonists

MP0310

FAP x CD40

DARPin® Platform

Mono-Specifics

37

Appendix

38

Dr. Patrick Amstutz, CEO

Co-founder, former CBO & COO

Member of the Board of Directors

PhD in molecular biology from UZH

Dr. Andreas Harstrick, CMO, MD

30 years of experience in oncology

Developed multiple mAb oncology products

Senior positions at Merck-Serono, Imclone, Eli Lilly

Dr. Michael Stumpp, COO

Co-founder

PhD and postdoc from UZH;

research in Tokyo, London

Andreas Emmenegger, CFO

Former CFO Glycart, Finance Roles at Roche

>20 years experience as CFO of private & listed

companies and in fund raising, IPOs

Dr. Pamela Trail, CSO

>30 years of experience in directing cancer drug

discovery at leading global pharma companies

Experienced Management Team & Board of Directors

Bill Burns, Chairman Former CEO of Roche Pharmaceuticals

Former board member of Roche, Genentech,

Chugai Pharmaceuticals, Shire

Göran Ando, Vice Chairman Former Chairman, Novo Nordisk

Former CSO, Pharmacia

Gwen Fyfe Former VP, Oncology Development at

Genentech

Steven H. Holtzman President and CEO, Decibel Therapeutics

Former EVP, Biogen

William “Bill” Lee EVP Research, Gilead

Petri Vainio Managing Director, Essex Woodlands

Ventures

EX

EC

UT

IVE

MA

NA

GE

ME

NT

BO

AR

D O

F D

IRE

CT

OR

S

39

(CHF million, except per share and FTE data) FY 2018 FY 2017 change

Revenues 10.4 20.0 (9.6)

Total expenses1 (47.8) (45.9) (2.0)

Operating result – EBIT (37.4) (25.8) (11.6)

Net financial result 0.4 0.4 0.0

Net result (37.0) (25.4) (11.6)

Basic net result per share (in CHF) (1.75) (1.22) (0.53)

Net cash used in operations (42.5) (40.0) (2.5)

Cash balance (incl. time deposits) as of Dec 31 99.02 141.13 (42.1)

Number of FTE’s as of Dec 31 117.7 107.8 9.9

Key Figures FY2018

1 Thereof non-cash costs of CHF 5.3mn in in FY2018 and CHF 5.0mn in FY20172 CHF 146m per January 31, 2019, including USD 50 million upfront payment collected from collaboration agreement with Amgen3 Including CHF 9.8m short-term time deposits

Note: Rounding differences may occur

40

• Total expenses of CHF 70-80 million,

of which around CHF 7 million non-cash effective costs

• Capital expenditures of ca. CHF 3 million

• No guidance on net cash flow;

timelines and potential milestones payments with partnerships not disclosed

• Guidance subject to progress and changes of pipeline

Financial Guidance for Full-Year 2019

41

Shareholder Structure

VC holdings halved vs. end 2016 to 23%

Listed on SIX Swiss Exchange (SIX: MOLN)

Included in key indices: SPI, SPI Extra,

SXI Life Sciences and SXI Bio+Medtech

21,228,593 shares outstanding

Ca. CHF 405 million market cap. as of Dec. 31, 2018

No lock-up restrictions in place

Formal free float as per SIX definition: 84%

Shareholder structure as of December 31, 2018

23%*

18%*

59%

Pre-IPO investors (4 VC's)

Management, Board, Founders

Others

Highlights

* According to SIX Swiss Exchange Filings

42

This presentation is not an offer to sell or a solicitation of offers to purchase or subscribe for shares of Molecular Partners AG, nor shall it or any part of it nor the fact of its

distribution form the basis of, or be relied on in connection with, any contract or investment decision. This presentation is not an offering circular within the meaning of Article 652a

of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies

of this presentation may not be sent to countries, or distributed in or sent from countries, in which this is barred or prohibited by law. This document is not a prospectus or a

prospectus equivalent document and investors should not subscribe for or purchase any securities referred to in this document. This document does not constitute a

recommendation regarding the shares.

This presentation contains specific forward-looking statements, beliefs or opinions, including statements with respect to the product pipelines, potential benefits of product

candidates and objectives, estimated market sizes and opportunities as well as the milestone potential under existing collaboration agreements, which are based on current beliefs,

expectations and projections about future events, e.g. statements including terms like “potential”, “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or

similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence

between the actual results, financial situation, development or performance of Molecular Partners AG and investments and those explicitly or implicitly presumed in these

statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts.

Past performance of Molecular Partners AG cannot be relied on as a guide to future performance. Forward-looking statements speak only as of the date of this presentation and

Molecular Partners AG, its directors, officers, employees, agents, counsel and advisers expressly disclaim any obligations or undertaking to release any update of, or revisions to,

any forward looking statements in this presentation. No statement in this document or any related materials or given at this presentation is intended as a profit forecast or a profit

estimate and no statement in this document or any related materials or given at this presentation should be interpreted to mean that earnings per share for the current or future

financial periods would necessarily match or exceed historical published earnings per share. As a result, you are cautioned not to place any undue reliance on such forward-

looking statements.

Unless stated otherwise the information provided in this presentation are based on company information. This presentation is intended to provide a general overview of Molecular

Partners AG’s business and does not purport to deal with all aspects and details regarding Molecular Partners AG. Accordingly, neither Molecular Partners AG nor any of its

directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance

should be placed on, the accuracy or completeness of the information contained in the presentation or of the views given or implied. Neither Molecular Partners AG nor any of its

directors, officers, employees, agents, counsel or advisers nor any other person shall have any liability whatsoever for any errors or omissions or any loss howsoever arising,

directly or indirectly, from any use of this information or its contents or otherwise arising in connection therewith.

The material contained in this presentation reflects current legislation and the business and financial affairs of Molecular Partners AG which are subject to change and audit.

Disclaimer

43

Molecular Partners AG

Wagistrasse 14

8952 Zürich-Schlieren

Switzerland

www.molecularpartners.com

T +41 44 755 77 00

IR Agenda

March 15, 2019 Expected Publication of Annual Report 2018

April 16, 2019 Annual General Meeting

May 9, 2019 Publication of Q1 Interim Management Statement